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Background: Bactericidal/permeability increasing protein fold containing family A (BPIFA) 1, is a secreted protein of the upper airways that shares
structural homology with BPI and exhibits comparable antimicrobial capacities. We hypothesized that CF patients have circulating IgG or IgA
anti-BPIFA1 autoantibodies, similarly as reported for BPI autoantibodies.
Methods: We analyzed pre- and post-transplantation sera from 67 endstage lung disease patients who underwent lung transplantation (LTx)
because of COPD (n = 27), CF (n = 25), and ILD (n = 15).
Results: Anti-BPIFA1 (48%) and anti-BPI (92%) were elevated in CF patients compared to healthy controls, with anti-BPIFA1 IgG isotype being
most prevalent, whereas anti-BPI is of the IgA isotype. Levels of anti-BPI autoantibodies signiﬁcantly declined post-LTx, whereas anti-BPIFA1
did not. No relation was found between autoantibodies against BPIFA1 and BPI.
Conclusion: Our results indicate that BPIFA1 is a novel target for autoantibodies in CF. The function of these autoantibodies needed to be
investigated in future studies.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: BPIFA1; Autoantibodies; BPI; Cystic ﬁbrosis; Lung transplantation1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder, which
mainly occurs in the Caucasian population.Morbidity andmortality
in patients with CFmostly relate to respiratory failure resulting from
chronic inflammation of the bronchi. Chronic infections by airwayAbbreviations: BPI, bactericidal/permeability increasing protein; BPIFA1
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ILD, interstitial lung diseases; LTx, lung transplantation; RF, rheumatoid
factor.
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;
;lishedpathogens, particularly Pseudomonas aeruginosa, contribute to
progressive impairment of pulmonary function [1]. For endstage
CF patients lung transplantation (LTx) is the final treatment
modality [1,2].
Autoantibodies against bactericidal/permeability increasing
protein (BPI) have been described in previous studies in patients
with both CF [3–6], and vasculitis [7]. BPI is a defense protein of
the host's innate immune system against gram-negative bacteria,
such as P. aeruginosa, and is expressed in neutrophils where it is
stored in acidic granules [8]. Epithelial cells, the first line of
defense against bacteria, may also express the protein [9]. The
presence of anti-BPI autoantibodies correlates with pulmonary
infections and poor prognosis in CF patients [6,10]. However, to
what extent autoantibodies against BPI in other endstage lung
diseases, including chronic obstructive pulmonary disease (COPD)
and interstitial lung diseases (ILD), occur, is unknown.by Elsevier B.V. All rights reserved.
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against a protein expressed by epithelial cells in 4 patients six
months after LTx [11]. Sequence reanalysis of the cloned gene
showed that these autoantibodies were actually recognizing the
PLUNC family variant SPLUNC1, a protein first described in the
trachea and bronchi of adult mice [12]. Because of the structural
homology of SPLUNC1 with BPI, the protein has recently been
renamed bactericidal/permeability increasing protein fold
containing family A (BPIFA) 1, due to the presence of a
single structural BPI fold domain [13,14]. Although there is
structural homology between BPI and BPIFA1, this is exclusively
based on the N-terminal region of BPI, a highly variant region.
Sequence alignments show that the structural homology is
primarily based on the secondary rather than the primary
structure of the protein [15].
BPIFA1 is mainly expressed in the upper regions of the
respiratory tract, accounting for 1% of the total protein load in
the airway surface liquid [16]. Specifically, BPIFA1 is expressed
the highest by epithelial cells in the lung and tracheobronchial
region, the submucosal glands of the trachea, and the bronchi [17].
More recently, neutrophils were also found to express PLUNC
family proteins, suggesting a more widespread distribution than
previously considered [18]. Various antimicrobial activities have
been attributed to BPIFA1, especially against P. aeruginosa
[19–22]. The structural homology between BPI and BPIFA1,
the antimicrobial effects of both BPI and BPIFA1, and the
clinical implications of bacterial infections in CF patients, led to
the hypothesis that CF patients also may have autoantibodies
against BPIFA1.
The aim of this study was to investigate whether anti-BPIFA1
occurs not only after, but also prior to LTx in patients with
endstage lung disease. We examined both the prevalence and
possible clinical relevance of BPIFA1 and BPI autoantibodies in
CF, COPD, and ILD. We also addressed the potential cross
reactivity between both autoantibodies since they recognize
structurally related proteins. As a control for autoantibodies, we
measured class-specific rheumatoid factors (RF), as these are
completely unrelated to infection with P. aeruginosa.
We describe, for the first time, the presence of autoantibodies
against BPIFA1 and that these autoantibodies are predominantly
found in patients with CF, and that autoantibody titres, contrary
to RF and BPI, are not affected by transplantation procedure or
immunosuppressive regime.
2. Patients and methods
2.1. Patients
A total of 67 patients undergoing lung transplantation (LTx)
between July 2002 and May 2011 at the Heart Lung Centre in
the Utrecht Medical Centre were included in this study. From
all patients informed consent was obtained and the study was
approved by the medical ethical committee. Blood was obtained
several hours prior to LTx and 6 months post-LTx, processed and
stored as serum aliquots at −80 °C. All patients received standard
immunosuppressive therapy consisting of basiliximab, tacrolimus,
mycophenolate mofetil and prednisone. Patients at risk for CMVwere treated with valganciclovir until 6 months post trans-
plantation. During follow up, 14 patients developed BOS, defined
as a decline of the forced expiratory volume in the first second
of expiration, FEV1, from the post-operative baseline at two
distinctive time-points by N−20% in the absence of apparent
causes such as infection [23]. Serum from 20 healthy volunteers,
which was also stored at −80 °C prior to analysis, was used as
control group.
2.2. Detection of autoantibodies against BPI, and BPIFA1, and
rheumatoid factors
Antibody levels were quantified with ELISAs using purified
native BPI (Athens Research & Technology, Inc., Athens, GA),
and purified recombinant BPIFA1 (OriGene Technologies, Inc.,
Rockville, MD), as antigens, respectively. Human serum albumin
(HSA, Albuman, Sanquin, The Netherlands) was used as a
background control. NUNC Maxisorp 96-well ELISA plates
(NUNC, Denmark) were coated with 1 μg/ml of the protein in
PBS for 3 h at room temperature. Final volume of this step as
well as all subsequent steps was 100 μl. After each step, plates
were washed three times with PBS 0.05%, w/v, Tween-20
(Bio-Rad Laboratories, Hercules, CA). Wells were blocked with
PBS containing 5%, w/v, HSA, 5%, w/v, sucrose (Sigma-Aldrich,
St. Louis, MO), and 0.005%, w/v, sodium azide (Sigma-Aldrich,
St. Louis, MO). Serum samples were diluted 1:10 and 1:50 in
dilution buffer, which was PBS containing 0.5% HSA and
0.05% Tween-20. The plates were then incubated with either
horse radish peroxidase (HRP)-conjugated rabbit anti-human
IgG (DakoCytomation, Denmark) or, HRP-conjugated rabbit
anti-human IgA (DakoCytomation, Denmark). Bound conju-
gated antibodies were visualized using a TMB substrate kit
(ThermoScientific, Rockford, IL) according to the manufacturer's
protocol. The OD450 was measured using a Multiskan EX
Microplate Photometer (ThermoScientific, Rockford, IL). The
inter- and intra-coefficients of variation for the IgG anti-BPI
and IgA anti-BPI ELISA were 4.1% and 6.4%, and 7.8% and
5.9%, respectively. For the IgG anti BPIFA1 the inter- and
intra-coefficients of variation were 3.6% and 10.2% and for
IgA anti-BPIFA1 1.1% and 13.4%.
In each assay, OD values obtained with individual serum
samples were corrected for background OD450 values obtained
with HSA coated plates. Dilutions of sera yielding a strong reaction
in the ELISA of IgG or IgA anti-BPI or anti-BPIFA1 were used as
a standard in the respective ELISA, and were set at 100 Arbitrary
Units per ml (AU/ml). Concentrations of anti-BPI or anti-BPIFA1
levels in each serum sample were calculated by comparing the
corrected OD450 values to those of the standard curves and
expressed as AU/ml. Although BPI and BPIFA1 autoantibody
titres are both expressed in AU, these titres are not quantitatively
comparable, since we used different sera as calibration standards.
IgG1 and IgG2 subclasses of the autoantibodies were
measured with the same ELISA procedures as described
above except that goat anti-human IgG1 or IgG2 was used
(both from The Binding Site, Birmingham UK) followed by
HRP-conjugated mouse anti-goat/sheep (Sigma-Aldrich, St.
Louis, MO). IgG3 and IgG4 subclasses were measured using
Table 1
Clinical and demographic profile of lung transplant patients. Patients are divided in three diagnostic clusters, chronic obstructive pulmonary disease (COPD), cystic
fibrosis (CF), and interstitial lung disease (ILD). Significant intergroup variations are displayed in italics.
All COPD CF ILD p-Value
Total number 67 27 25 15
Gender
Male 31 8 15 8 0.074
Female 36 19 10 7
Mean age 44 (16–63) 53 (32–63) 31 (16–53) 49 (24–62) b0.0001
Mean follow up (months) 54 (5–124) 49 (7–124) 56 (5–105) 62 (9–95) 0.155
Type of graft
Bilateral 54 17 25 12 0.003
Single 13 10 0 3
Infection
EBV high risk 6 2 4 0 0.226
CMV high risk 17 2 12 3 0.003
BOS
No 53 20 20 13 0.624
Yes 14 7 5 2
Onset of BOS (months) 31 (5–81) 35 (16–81) 33 (5–49) 13 (9–17) 0.409
Ischemic time (minutes)
Bilateral 297 (124–1460) 255 (124–405) 288 (145–765) 375 (165–1460) 0.053
Single 223 (161–337) 210 (182–265) 252 (161–337) 0.272
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SouthernBiotech, Birmingham, AL). The presence of IgA1 or
IgA2 subclasses was determined using mouse HRP-conjugated
anti-human IgA1 or IgA2, (both obtained from SouthernBiotech,
Birmingham, AL). Reagents needed to assess IgG- and IgA-RF
were kindly provided by Thermofischer Scientific and concen-
trations were measured on the Phadia ImmunoCAP 250 ac-
cording to the manufacturer's protocol (Thermofischer Scientific,
Nieuwegein, The Netherlands).
2.3. Statistics
Categorical data (gender, risk for CMV/EBV, BOS) were
analyzed by the Fisher's exact test, continuous variables (mean
age, follow up, and the onset of BOS) by the ANOVA test, and
influence of the type of graft (bilateral or single) by the
Pearson's χ2 test. Autoantibody titres pre- and post-LTx were
compared using the Wilcoxon signed-rank test, whereas the
Mann–Whitney rank-sum test was used to compare titres
between CF, COPD, ILD and healthy controls. Correlations
between IgA and IgG autoantibodies against BPI, BPIFA1 and
RF were determined using the Spearman's rank correlation. A
p-value ≤0.05 was considered to be statistically significant.
3. Results
3.1. Patient characteristics
The cohort included in this study consisted of 67 LTx patients,
of whom 27 suffered from COPD, 25 from CF and 15 from ILD.
The mean age of the patients at inclusion was 44 years (range 16–
63 years). Fourteen patients developed BOS post-LTx. Further
demographic and clinical details by subgroup are summarized in
Table 1. CF patients were younger than the other patients, andreceived a bilateral transplantation in 100% of cases. Probably
because of their younger age at the time of transplantation, CF
patients had less frequently positive serology for CMV than COPD
or ILD patients. All other demographic parameters were similar in
each diagnostic cluster.
3.2. IgG anti-BPIFA1 is increased in patients with cystic
fibrosis
All sera taken prior to transplantation were screened for the
presence of anti-BPIFA1 (IgG and IgA), anti-BPI (IgG and
IgA) and rheumatoid factors (IgG and IgA). IgG anti-BPIFA1
autoantibody titres were significantly higher in CF patients than in
healthy controls (HC) and COPD patients (p = 0.0005) whereas
ILD patients only had significantly higher IgG anti-BPIFA1
autoantibody titres than HC (Fig. 1A). IgG anti-BPIFA1 had a
specificity of 88% for CF. A similar pattern was found for IgA
anti-BPIFA1 autoantibody titres. Autoantibody levels in CF
patients were higher than in HC (p = 0.007) or COPD patients
(p = 0.04). ILD patients only had significantly higher IgA anti
BPIFA1 levels when compared to HC (p = 0.03, see Fig. 1B), but
titres are elevated in multiple disease states. In the CF diagnostic
subgroup, an IgG anti-BPIFA1 positive and negative group was
found. We observed a trend (p = 0.09) for the association of IgG
anti-BPIFA1 and diabetes mellitus (see Fig. 2).We did not observe
significant differences between pre- and post-LTx levels of both
IgG and IgA anti-BPIFA1 autoantibody titres. These levels also did
not correlate to any demographic or clinical parameters.
IgG anti-BPI autoantibody levels were higher in CF patients
than in HC (p = 0.006, Fig. 1C), whereas levels in COPD and ILD
were similar as in HC. However, IgA anti-BPI autoantibody levels
in CF patients were significantly higher than those found in HC
and in COPD and ILD patients (p = b0.0001, Fig. 1D), and
showed a specificity of 73% for CF. Subclass analysis of IgGαBPI
A B
C D
E F
Fig. 1. Pre transplant autoantibody levels against BPIFA1, BPI and RF. Autoantibody titres are displayed in arbitrary unit/ml (AU/ml) for IgG anti-BPIFA1 (A), IgA
anti-BPIFA1 (B), IgG anti-BPI (C), IgA anti-BPI (D), IgG RF (E), and IgA RF (F). A minimal detection level of 1 AU/ml was used for both BPIFA1 and BPI
autoantibodies. Patients are represented by open circles and the median by a horizontal bar. For BPI and BPIFA1 autoantibodies, the cut off was determined as the
mean titre of HC + 2 × SD. The cut off for IgA RF positivity was set according to manufacturer's instructions, but was not available for IgG RF. Measurements were
performed as described in Section 2.2 of the Patients and methods section.
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whereas IgAαBPI autoantibodies all consisted of the IgA1 subtype
(data not shown). Post-LTx measurement of IgG and IgA auto-
antibody titres did not show any significant differences among
subgroups.
IgG and IgA RF were significantly higher in CF patients
than in ILD and COPD, although the median level of IgA RF
was below the cut-off level for positivity. The cut-off level was
not available from the manufacturer for IgG RF. IgG RF was
elevated in 11% of the COPD patients, 15% of the CF patients,
and 12% of the ILD patients. For IgA RF was elevated in 9% of
the COPD patients and 22% of the CF patients (Fig. 1E and F).Similarly to anti-BPIFA1 and anti-BPI post-LTx autoantibody
titres, we found no significant differences in both IgG and IgA
RF. Also, no patients had RF titres above cut-off value for
positivity.
3.3. Lung transplantation affects levels of autoantibodies,
except IgG anti-BPIFA1
To examine the influence of lung transplantation on auto-
antibody levels, titres were expressed as ratio of autoantibody
levels to total Ig isotype levels (Fig. 3). No significant change
in IgG anti-BPIFA1 or IgA anti-BPIFA1 autoantibody ratio
Fig. 2. Cystic fibrosis related diabetes mellitus and IgG anti-BPIFA1. CF
patients have been divided into two groups, with or without CF related diabetes
mellitus and compared for their respective IgG anti-BPIFA1 autoantibody titres.
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population (Fig. 3A and B). However, a small but significant
decline was observed in the ratio of IgG anti-BPI/total IgG in
pre- and post-LTx sera (4.94, versus 4.26, p = 0.009, see
Fig. 3C). More pronounced differences were found for pre- and
post-LTx IgA anti-BPI (25.35 versus 6.80, p = 0.008, see
Fig. 3D). This decrease was also found for RF. Ratios of total
IgG-RF/total IgG decreased on average by 2.4 upon LTx (Fig. 3E).
A similar reduction was observed for IgA RF titres, decreasing by
3.4 (Fig. 3F). Thus, the lung transplantation procedure did not
influence levels of anti-BPIFA1, but significantly reduced levels of
anti-BPI and RF. Changes in autoantibody titres did not correlate
with any demographic or clinical parameter, including BOS de-
velopment, age, sex, ischemic time or risk for CMV or EBV
reactivation. Donor characteristics such as age and smoking history
also did not correlate with the change in autoantibody levels
against BPIFA1 and BPI either.
4. Discussion
In this study, we have identified a novel autoantibody against
BPIFA1, an antimicrobial protein which shares structural
homology with bactericidal permeability increasing protein
(BPI) and exhibits similar antimicrobial capacities. Anti-BPI
and anti-BPIFA1 autoantibodies were the highest in CF patients,
although their main isotypes were different, as was their responses
to LTx or immunosuppressive therapy.
Autoantibodies against BPI correlate with pulmonary infections
and poor prognosis in patients with CF. Carlsson et al. observed a
decrease in IgA BPI-ANCA in seven CF patients who underwent
LTx, although both pre- and post-LTx measurements were at large
time intervals [6]. A decline in post LTx autoantibody titres in CF
patients who underwent LTx or extensive sinus surgery was also
observed by Aanaes et al., and they speculated that surgical
eradication of the infectious focus and the reduction in mucosal
inflammation reduce levels of autoantibodies against BPI [24]. We
also observed a decrease of autoantibodies against BPI in themajority of CF patients upon LTx. However, decreasing
autoantibody titres in our cohort were found not only in CF,
but also in COPD and ILD patients. These decreases cannot
be due to a general effect of LTx and immunosuppression
since titres of another autoantibody, i.e. anti-BPIFA1, did not
show a similar course. Therefore, one may speculate that IgA
anti-BPI, when elevated in patients with infectious-inflammatory
disease, will decrease in the case of effective removal of the
infectious-inflammatory lesions. However, in each subgroup we
also observed increases of IgA anti-BPI in individual patients.
Such increases did not correlate with re-infection, or any other
clinical parameter.
In the past years, various functions have been attributed to
BPIFA1. The structural homology between BPIFA1 and BPI
suggests an antimicrobial activity and several studies have
demonstrated this. In a paper by Chu et al. it was shown that
growth of Mycoplasma pneumoniae was significantly reduced
in the presence of recombinant murine BPIFA1 [19]. Zhou et
al. demonstrated that BPIFA1 binds lipopolysaccharide and
inhibits growth of P. aeruginosa in vitro in a dose-dependent
manner [20]. Lukinskiene et al. showed that transgenic mice in
which human BPIFA1 was expressed by the airway epithelium,
displayed enhanced bacterial clearance after in vivo P. aeruginosa
challenge. Also, overexpression of this construct led to a higher
survival rate of mice after P. aeruginosa infection [21]. Finally,
Gakhar et al. suggest that BPIFA1 contributes to the surfactant
properties of airway secretions thereby possibly interfering with the
biofilm formation of airway pathogens [22].
Autoantibodies against BPI in CF patients are directed at
both C-terminal and N-terminal epitopes [25], and we cannot
rule out the possibility of cross-reactivity between anti-BPI
and anti-BPIFA1. However, because both autoantibodies are
of a different isotype, and there is a different influence of LTx
on autoantibody titres, we conclude that it is most likely that
autoantibodies against BPIFA1 and BPI recognize a different
epitope, and are exclusively directed against a single protein.
We describe here the presence of both IgG and IgA
autoantibodies against BPIFA1 in endstage CF patients. We
identified these autoantibodies in CF patients with advanced
disease progression, and our findings are therefore not necessarily
representative of less advanced disease stages. It is reasonable to
expect that advanced disease progression is associated with more
tissue damage and more autoantibody production. Therefore, it
would be highly interesting to analyze autoantibody production
development during disease progression in a longitudinal cohort
of CF patients.
IgG and IgA anti-BPIFA1 autoantibody levels did not decrease
upon LTx and immunosuppressive therapy. This is in contrary to
the antibody titres of anti BPI and RF. We reason that there is a
different mechanism of autoantibody production underlying this
observation. Also, we did not find a correlation between the change
of autoantibody titres and clinical or demographic parameters.
We can only speculate on the potential pathogenic role of
anti-BPIFA1. Along with anti-BPI, multiple other autoantibodies
are prevalent in CF, such as anti-Saccharomyces cerevisiae
antibodies, anti-Kα1 tubulin, anti-collagen-V, rheumatoid factors
and antinuclear antibodies. Besides the fact that a delineation of
A B
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Fig. 3. Autoantibody titres pre- and post-lung transplantation. We measured autoantibody titres pre and post LTx for IgG anti-BPIFA1 (n = 31, A), IgA anti-BPIFA1
(n = 24, B), IgG anti-BPI (n = 32, C), IgA anti-BPI (n = 25, D), IgG RF (n = 32, E), and IgA RF (n = 25, F). Pre- and post-LTx IgG and IgA autoantibody titres,
measured in arbitrary units/ml (AU/ml) were corrected for the total level of IgG or IgA, in μg/ml, measured at the same time point, and the ratio is displayed on the
y-axis. A minimal ratio of 0.2 was used for IgG anti-BPIFA1 and 1 for IgA anti-BPIFA1 and both isotypes of anti-BPI. Patients in this paired comparison are depicted
by open circles. Measurements were performed as described in Section 2.2 of the Patients and methods section.
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patients at risk for developing lung damage, autoantibodies have
potential significant clinical impact in airway disease, as was
shown for autoelastin antibodies in COPD [26]. Interestingly,
autoantibodies against BPI directly inhibit the antibiotic function
mediated by the N-terminal region of the protein [27]. It is
reasonable to assume that BPIFA1 autoantibodies operate in a
similar way, resulting in a less functional part of the innate immune
system that might have an impact on disease progression.
Whereas an anti BPI autoantibody is, in ANCA immu-
nofluorescence terminology, an atypical c-ANCA, or p-ANCA
without nuclear extension, we did not observe any fluorescent
staining when we analyzed anti-BPIFA1 positive sera using thediagnostic ANCA protocol (Euroimmun, Lübeck, Germany),
despite the fact that PLUNC is a secreted product of neutrophil
granules [18]. However, the study of Bartlett et al. was conducted
before the differentiation of PLUNC variants based on BPI
homology. It could therefore be possible that autoantibodies
against BPIFA1 do not recognize the PLUNC variant expressed
by neutrophils.
BPIFA1 is highly expressed in the upper respiratory tract and
interestingly, BPIFA1 expression is increased in the epithelium
of small airways in advanced CF patients compared to healthy
controls, patients with emphysema or patients with pneumonia
[28]. Taking the antimicrobial capacities of BPIFA1 and the
chronic state of infection of these patients into consideration, we
287K. Budding et al. / Journal of Cystic Fibrosis 13 (2014) 281–288reason that this highly immunoactive region could contribute to
autoantibody production. Bingle et al. showed no expression of
BPIFA1 by either neutrophils or macrophages, making the
literature on the expression of BPIFA1 by neutrophils not
conclusive [18,28]. We therefore conclude that the source for the
auto-antigen BPIFA1 is the epithelial cells of small airways.
Although the antigenic source for anti-BPIFA1 autoantibodies is
replaced after LTx procedure, we did not observe a decline in
autoantibody levels. Activation of donor lung epithelial cells after
transplantation due to the recipient's alloimmune response could
lead to an increased expression of BPIFA1, thereby maintaining
antigen levels. This could explain the difference in autoantibody
titres between anti-BPI and anti-BPIFA1 post-LTx since immu-
nosuppression could have a different impact on the source of the
antigens.
The identified autoantibodies against BPIFA1 did not correlate
with demographic parameters, though we observed a trend
between IgG anti-BPIFA1 positivity and the incidence of CF
related diabetes mellitus. The development of CF related
diabetes is associated to chronic infection in CF patients, and
the development of these autoantibodies could be used as a
tool to identify patients at risk for this clinical outcome.
Considering the antimicrobial capacities of BPIFA1, we propose
a model wherein autoantibody production against BPIFA1 leads
to a deregulated innate immune response and a failed clearance
of P. aeruginosa. However, both the clinical and diagnostic
implications of anti-BPIFA1 need to be established in future
studies.
RF may develop upon chronic exposure to cigarette smoke,
and COPD patients, both smokers and ex-smokers, are 100%
positive for IgA RF [29]. We did not confirm this data in our LTx
cohort, since we detected significantly higher levels of IgG and
IgA RF in CF patients, compared to both COPD and ILD, though
a number of patients had undetectable levels. All LTx patients
ceased smoking half a year prior to entering the waiting list. Also,
there are no ever-smokers in the CF patient group. Therefore, we
found no relation between the presence of IgG and IgA RF and
smoke exposure. This difference with published literature may be
due to the use of a different assay, though we used a commercial
validated IgA RF kit. We found a correlation between IgA RF
and IgA anti-BPI. Moreover, both isotypes of RF showed a
similar course upon LTx and immune suppression. Considering
the fact that production of RF is T cell dependent [30], one may
speculate that decreasing RF titres simply reflected the use of
immunosuppressive therapy. However, as stated above, levels of
anti-BPIFA1 did not show such course, making this interpretation
less likely. Therefore we suggest that RF titres, similarly to
anti-BPI titres, decreased because of reduced infectious and
inflammatory burden in the patients. Indeed, infections can
trigger RF production in humans [31].
In summary, we have identified a novel autoantibody against
BPIFA1 in CF patients. Isotype distribution and response to LTx
and immunosuppressive therapy of these autoantibodies seem
different to those of anti-BPI autoantibodies. Further studies
are needed to elucidate the origin, the pathogenicity and the
potential role of biomarkers for lung damage of these autoan-
tibodies in CF.Conflict of interest
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